-
Mashup Score: 5Dupilumab for Atopic Dermatitis: 7 Years Later - 1 month(s) ago
Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here’s a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 5Dupilumab for Atopic Dermatitis: 7 Years Later - 2 month(s) ago
Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here’s a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 0
Children treated with dupilumab showed improved lung function compared with placebo group, according to one study.
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Dupilumab’s efficacy was sustained through the 260-week open-label study.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 2Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: A case series - 7 month(s) ago
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a type IV hypersensitivity reaction manifesting with internal organ involvement, lymphadenopathy, hematologic abnormalities, and cutaneous lesions.1 Common culprits include allopurinol, antiepileptics, and antibiotics. Systemic corticosteroids are the mainstay of active intervention for this severe cutaneous adverse reaction (SCAR); however, this is associated with negative side effects, particularly with prolonged use, as is often required for DRESS.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Promising Results for Dupilumab in Treatment of Moderate-to-Severe COPD with Type 2 Inflammation - 8 month(s) ago
This new data on dupilumab demonstrates the drug’s potential usefulness in treating type 2 inflammation, a role which is central to respiratory diseases including COPD.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
These findings highlight the potential of dupilumab treatment in improving lung function among children that are shown to have uncontrolled, moderate-to-severe type 2 asthma.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
This new data indicates that dupilumab in this patient population had favorable efficacy and safety, though some unique concerns were risk of infection and eosinophilia.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
This new data indicates that dupilumab in this patient population had favorable efficacy and safety, though some unique concerns were risk of infection and eosinophilia.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0AD Patient Self-Confidence and Satisfaction Improved With Dupilumab Self-Injection - 10 month(s) ago
Dupilumab self-injection has been available to patients in Japan since May 2019.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet
Today now marks 7 years to the date that #dupilumab received a US FDA approval for atopic dermatitis. Dermatology Times reflects on the timeline of dupilumab over the years, including strides and approvals made during this time. https://t.co/tdVvDcQTKw